NTT Com Launches Renewed SkyWay SDK for More Versatile Development of Online Communication Services
31.1.2023 13:01:00 EET | Business Wire | Press release
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT group, announced today the immediate launch of the renewed SkyWay software development kit (SDK). The new SkyWay SDK makes it easier than ever to implement real-time voice, video and data communication for applications and websites.
People interested planning or developing online communication services may apply to attend a free webinar in person (50 people) or online (100 people) to learn about the renewed SkyWay SDK at NTT Communications' Tokyo headquarters from 3:00pm (JST) on February 23.
Simple to use and supported with extensive documentation, SkyWay does not require special technical skills or knowledge of voice/video communication or constructing servers, and can be used for a wide range of applications, such as online lessons, IoT and robots. To date, SkyWay has been deployed for the development of more than 20,000 services.
SkyWay is suitable for diverse call formats including voice and video, one-to-one and group calls, and video communication while sharing screens. It also is a multiplatform SDK for developing communication services suited to specific industries and business categories. SkyWay assures high-quality real-time communication, as evidenced by its service uptime rate of 99.96% in fiscal 2021. It also achieves high-quality overseas calls by setting up servers to relay communications to/from Asia, North America and Europe.1 What's more, SkyWay may be used at no charge for service verification and development until the users service is actually launched. Furthermore, fees are adjusted to the scale of service and billing is implemented on a pay-as-you-go billing basis.
Due to the COVID-19 pandemic, online communication has rapidly diversified and now commonly includes events involving dozens of people as well as communication robots. In response, NTT Com decided to upgrade SkyWay's architecture and release it as a new service with enhanced functions for increased versatility, including:
- More simultaneous callers (expanded from 20 to 100 max.)
- Terminal load reduction according to end-user environment (simulcasting2 and API for flexible media transmission/reception, such as only specific video/audio)
- Authentication and authorization for controlling transmission of video/audio to each end user
The following are two examples of SkyWay's expanded functionality.
1. Virtual office
SkyWay can be used to create a system for an office-wide presentation reaching up to 100 people, with simulcasting allowing people to receive audio/video suitably adjusted to each user, such as low-resolution video to reduce system and battery load for mobile devices or terminals with low processing power. Also, participation can be controlled for private conferences.
2. Remote work support
SkyWay also can be used to create a system that allows a supervisor to remotely instruct multiple people at a worksite, using video for detailed directions and only audio if simple verbal directions are sufficient. Selective use of video and/or audio enables the system to reach many people with minimum load.
Service applications will be accepted from January 31. For details, please visit the website or contact a NTT Com sales representative, and for service rates, please see here. (Partially in Japanese only)
Looking ahead, NTT Com expects to further upgrade SkyWay by expanding the scale of voice and video calls, enhancing data communications for synchronization of more people, and supporting gaming platforms for live streaming and the metaverse. In addition, voice and video call experiences will be improved. Also, new SkyWay functions for measuring quality and analyzing problems will increasingly upgrade video and voice in diverse environments. Going forward, NTT Com will continue to develop SkyWay-related business to support the further evolution of real-time communication and its easy implementation by nonexperts in a world where people communicate meaningfully through the power of digital technology.
For more information about SkyWay, please visit here.
1 Technology that enables a terminal to select the most appropriate relay device in order to minimize delay between terminals (granted patent No. 6254620).
2 Technology for transmitting the same video to different terminals using different bitrates, such as low-resolution to mobile devices with limited processing power and bandwidth and high-resolution to PCs.
About NTT Communications
NTT Communications solves global technology challenges by helping enterprises utilize managed IT-infrastructure solutions to overcome complexity and risk in their IT environments. These solutions are backed by our worldwide infrastructure, including industry-leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2 of the world's most advanced data-center facilities. As the core provider of the DOCOMO group's enterprise-business services and solutions, we create value by providing global-scale support for restructuring in industry and society, new workstyles and digital transformation in communities. Together with NTT Ltd., NTT Data and NTT DOCOMO, we are the NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005787/en/
Contact information
For more information
SkyWay Promotion Office
Platform Service Division
NTT Communications Corporation
E-mail: skyway@ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom